Laura Spring, MD

Exciting Data in the Treatment of HER2-low from SABCS 2023

March 28th 2024

Laura Spring, MD, and Manali Bhave, MD, highlight promising new systemic treatment options on the horizon for patients with metastatic breast cancer, including T-DM1 for HER2-low disease, the AKT inhibitor capivasertib, and novel endocrine therapies.

Sequencing Antibody-Drug Conjugates (ADCs) in HR+/HER2-Low Metastatic Breast Cancer

March 28th 2024

Laura Spring, MD, and Manali Bhave, MD, discuss sequencing approved antibody-drug conjugates, T-DM1 and sacituzumab govitecan, for hormone receptor-positive, HER2-low metastatic breast cancer after progression on chemotherapy.

Factors for Consideration When Choosing Among Options for Patients with ET-resistant ER+/HER2- mBC

March 21st 2024

Oncologists discuss considerations for systemic therapy selection beyond first-line endocrine-based regimens in recurrent hormone receptor-positive, HER2-low metastatic breast cancer, including use of additional endocrine therapy combinations, chemotherapy, and supportive care approaches.

Approaches to Mutation Testing for Patients With HR+/HER2-low mBC and ET-Resistant Disease

March 21st 2024

Laura Spring, MD, and Manali Bhave, MD, discuss considerations for systemic therapy selection in a patient with recurrent hormone receptor-positive, HER2-low breast cancer, including use of plasma and tissue genomic testing and endocrine therapy sequencing based on factors like prior response and ESR1 mutation status.

Clinical Scenario: A 65-Year-Old Post-Menopausal Woman With Metastatic Breast Cancer

March 14th 2024

Oncologists present the clinical scenario of a 65-year-old woman with recurrent HR-positive, HER2-low breast cancer, and discuss optimal sequencing of systemic therapies in this setting.

Sequencing Therapies in the Third-Line and Beyond for Patients With HER2+ Metastatic Breast Cancer

March 14th 2024

Doctors Laura Spring and Manali Bhave discuss summarize their recommended sequence of systemic therapy options for HER2-positive metastatic breast cancer, from first-line taxane and dual HER2 blockade through later lines with T-DM1, tucatinib, and other regimens.

Standard of Care Regimens for Second-Line Treatment of HER2+ Metastatic Breast Cancer

March 7th 2024

Laura Spring, MD, and Manali Bhave, MD, discuss findings from the DESTINY-Breast03 trial and how these results have led them to adopt T-DM1 as the new standard of care over lapatinib/capecitabine for second-line treatment of HER2-positive metastatic breast cancer after progression on first-line trastuzumab and a taxane.

Key Clinical Trials in the First-Line Treatment of HER2+ Metastatic Breast Cancer

March 7th 2024

Oncologists discuss key learnings from clinical trials investigating the first-line treatment of patients with HER2-positive metastatic breast cancer, and how these findings help inform their clinical practice regarding selection of optimal systemic therapy regimens.

Current First-Line Systemic Therapy Options for HER2+ Metastatic Breast Cancer

February 29th 2024

Experts discuss considerations around first-line treatment selection for HER2-positive metastatic breast cancer, including when to diverge from the standard-of-care treatment, as well as the role of brain MRIs at diagnosis.

Clinical Scenario: A 57-Year-Old Woman With Metastatic Breast Cancer

February 29th 2024

Two oncologists present the clinical scenario of a 57-year-old woman with metastatic HER2-positive breast cancer to discuss their approach for incorporating recent research into clinical decision making around systemic therapy.

Dr. Spring on Next Steps of the AMEERA-1 Trial in ER+/HER2- Advanced Breast Cancer

February 2nd 2022

Laura Spring, MD, discusses next steps of the phase 1/2 AMEERA-1 trial in estrogen receptor–positive, HER2-negative advanced breast cancer.

Dr. Spring on the Rationale for the AMEERA-1 Trial in ER+/HER2- Advanced Breast Cancer

February 1st 2022

Laura Spring, MD, discusses the rationale for the ongoing phase 1/2 AMEERA-1 trial in estrogen receptor–positive, HER2-negative advanced breast cancer.

Precision Medicine in Metastatic Triple Negative Breast Cancer

September 16th 2020

HER2+ Early-Stage Breast Cancer: Peri-Operative Therapy

September 16th 2020

Metastatic HER2+ Breast Cancer

September 16th 2020

Metastatic HR+ Breast Cancer

September 16th 2020

Dr. Spring on the Association Between pCR and Neoadjuvant Chemotherapy

December 7th 2018

Laura Spring, MD, medical oncologist at Massachusetts General Hospital Cancer Center and instructor in medicine at Harvard Medical School, discusses the association between pathologic complete response (pCR) and neoadjuvant chemotherapy in patients with breast cancer at the 2018 San Antonio Breast Cancer Symposium.